EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma

Zhou Liu, Liang Zhang, Wei Peng, Qianqian Chen, Yanguang Hou, Liying Zhan, Guang Li

Frontiers in Pharmacology · 26.02.2025 · 16

DOI: 10.3389/fphar.2025.1543612 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.02.2025. Verfasst von Zhou Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, Renmin Hospital of Wuhan University, Wuhan, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case report describes a geriatric male patient with myasthenia gravis (MG) secondary to giant thymoma, presenting with progressive muscle weakness and ptosis. The diagnosis of MG was confirmed through pathology, imaging, and laboratory evaluations. Considering the significant surgical risks associated with the giant thymoma, adjuvant chemotherapy was initiated. Unfortunately, 2 weeks following chemotherapy, the patient developed acute respiratory failure and sudden loss of consciousness. Emergency endotracheal intubation was performed, and he was then transferred to the intensive care unit (ICU) and treated with immunoglobulin, plasmapheresis, prednisone, and pyridostigmine. During ICU hospitalization, the patient developed severe lower limb edema accompanied by increased skin temperature, particularly on the left side. Ultrasound imaging confirmed extensive thrombosis in the left iliac and femoral veins, with thrombosis involving 50%–67% of the venous lumen. To prevent the risk of pulmonary embolism (PE), an inferior vena cava filter was implanted, and low-molecular weight heparin (LMWH) was prescribed for anticoagulation. Unfortunately, the patient later experienced intermittent melena and heparin-induced thrombocytopenia (HIT), with hemoglobin levels decreasing to 55 g/L and platelet counts decreasing to 57 × 10 9 /L. Given the adverse events associated with LMWH, sulodexide (SDX) was substituted as a novel anticoagulant with multiple benefits, including reduced thrombosis and bleeding risk, anti-inflammatory effects, and vascular endothelium protection. SDX demonstrated excellent efficacy and safety, with no adverse effects observed during the 3-year follow-up period. In conclusion, SDX should be considered an ideal potential option for long-term anticoagulation in patients with complex conditions such as MG with both thrombotic and bleeding risks.

Schlagwörter

Stichwörter der Autor:innen

anti-thrombosisanticoagulationmyasthenia gravissulodexidevenous thrombosis

Autor:innen und Institutionen

  • Department of Intensive Care Unit, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Radiology, Renmin Hospital of Wuhan University, Wuhan, China.

Zitieren

APA

Liu, Z., Zhang, L., Peng, W., Chen, Q., Hou, Y., Zhan, L., & Li, G. (2025). Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1543612

Vancouver

Liu Z, Zhang L, Peng W, Chen Q, Hou Y, Zhan L, et al. Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1543612

BibTeX
@article{Liu2025,
  author = {Liu, Zhou and Zhang, Liang and Peng, Wei and Chen, Qianqian and Hou, Yanguang and Zhan, Liying and Li, Guang},
  title = {Advances in sulodexide-based long-term anticoagulation for a myasthenia gravis patient with giant thymoma},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1543612}
}
Kostenlos starten →